Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Guardant Health, Inc.    GH

GUARDANT HEALTH, INC.

(GH)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/06/2019 11/07/2019 11/08/2019 11/11/2019 11/12/2019 Date
64.65(c) 64.2(c) 71.89(c) 72.97(c) 73.56 Last
1 184 622 1 461 419 3 794 745 1 043 340 2 080 038 Volume
-4.91% -0.70% +11.98% +1.50% +0.81% Change
More quotes
Financials (USD)
Sales 2019 187 M
EBIT 2019 -110 M
Net income 2019 -110 M
Debt 2019 -
Yield 2019 -
Sales 2020 254 M
EBIT 2020 -111 M
Net income 2020 -120 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -52,4x
P/E ratio 2020 -46,2x
Capi. / Sales2019 32,2x
Capi. / Sales2020 23,6x
Capitalization 6 010 M
More Financials
Company
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage... 
More about the company
Surperformance© ratings of Guardant Health, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on GUARDANT HEALTH, INC.
11/07GUARDANT HEALTH : 3Q Earnings Snapshot
AQ
11/07GUARDANT HEALTH, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
11/07GUARDANT HEALTH, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
11/07Guardant Health Reports Third Quarter 2019 Financial Results and Raises 2019 ..
GL
11/06MASAYOSHI SON : SoftBank's Son admits mistakes after Vision Fund's $8.9 billion ..
RE
11/05SoftBank's Tech Problems Widen -- WSJ
DJ
11/04Snakes and ladders - SoftBank Vision Fund's climbing, sliding valuations
RE
11/04Guardant Health to Report Third Quarter 2019 Financial Results on November 7,..
GL
10/23Guardant Health Initiates ECLIPSE Pivotal Study for its LUNAR-2 Blood Test fo..
GL
09/28Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification D..
GL
09/24WeWork's IPO Delay Threatens SoftBank -- WSJ
DJ
08/06GUARDANT HEALTH : 2Q Earnings Snapshot
AQ
08/06GUARDANT HEALTH, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
08/06GUARDANT HEALTH : Reports Second Quarter 2019 Financial Results and Raises 2019 ..
AQ
08/05Largest Study of its Kind Finds Guardant360 MSI Highly Concordant to Tissue
GL
More news
News in other languages on GUARDANT HEALTH, INC.
05/30Vision Fund veut garantir un prêt par ses parts dans Uber
More news
Analyst Recommendations on GUARDANT HEALTH, INC.
More recommendations
Sector news : Bio Diagnostics & Testing
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
11/06Biogen Adding Ophthalmology Biosimilars in Deal With Samsung Bioepis
DJ
11/06CELLTRION : 3Q Net Profit Rose 13% on Year
DJ
11/05Regeneron Pharmaceuticals Up Over 9%, on Pace for Largest Percent Increase Si..
DJ
More sector news : Bio Diagnostics & Testing
Chart GUARDANT HEALTH, INC.
Duration : Period :
Guardant Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GUARDANT HEALTH, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 115,80  $
Last Close Price 64,65  $
Spread / Highest target 109%
Spread / Average Target 79,1%
Spread / Lowest Target 23,7%
EPS Revisions
Managers
NameTitle
Helmy Eltoukhy Chief Executive Officer & Director
AmrAli H. Talasaz Chairman, President & Chief Operations Officer
Derek A. Bertocci Chief Financial Officer
Richard B. Lanman Chief Medical Officer
Samir Kaul Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GUARDANT HEALTH, INC.94.12%6 010
GENSCRIPT BIOTECH CORPORATION78.48%4 764
IOVANCE BIOTHERAPEUTICS, INC.169.72%2 682
INVITAE CORPORATION60.85%1 509
MIRACA HOLDINGS INC.11.02%1 389
VERACYTE, INC.86.65%1 163